key: cord-1036753-9jnc3abu
authors: Hasbal, Nuri Baris
title: Thrombotic microangiopathy: COVID-19 or Hydroxychloroquine?
date: 2020-09-22
journal: Kidney Int
DOI: 10.1016/j.kint.2020.08.030
sha: 1323ab847df6728eb508972d7c1fd17e1e2995c0
doc_id: 1036753
cord_uid: 9jnc3abu

nan

To the Editor, I read with great interest the Letter to the Editor by Jhaveri et al. reporting the first published case report of thrombotic microangiopathy in a patient with COVID-19. 1 While there was a clear temporal relationship between the presentation with COVID-19 and development of thrombotic microangiopathy, I wonder whether the authors considered the possibility of a drug-induced thrombotic microangiopathy in particular hydroxychloroquine which was introduced on Day 1 of admission.

The novel coronavirus pandemic has led to unprecedented challenges not only to health care delivery but also to the world's economies. This highly transmissible virus with no effective vaccine or anti-viral therapy has, to date, infected over 16 million people and led more than 600,000 deaths in 213 countries and territories worldwide (https://www.worldometers.info/coronavirus/coronavirus-death-toll, accessed 26 July 2020). At the start of this pandemic, hydroxychloroquine provided a glimmer of hope following early reports of in vitro anti-viral activity against the SARS-CoV-2 virus. The surge in off-label use of this agent prior to any clinical trial proving benefit against COVID-19 has brought to light many of its side-effects including drug-induced thrombotic microangiopathy. Although the COVID-19 is highly associated with thrombosis as stated by the authors in the report, drug induced thrombotic microangiopathy should also be considered in this setting.

The casual relationship between a drug and an adverse event may be probable, possible or unlikely. While clues can be gathered from the adverse effect history of a drug, clinical presentation and time onset of symptoms in relation to drug exposure, proving a causal relationship is unfortunately not always easy. Although the time elapsed between the development of thrombotic microangiopathy findings after drug initiation is not typical, generally it is presented within a day after starting medication, the signs and symptoms are highly determinative for drug-mediated thrombotic microangiopathy in the case.

There are two different types of drug-mediated thrombotic microangiopathy: immune and toxic dose-related reactions. 2 The first and most commonly reported immune-mediated reaction has been associated with the antimalarial drug, quinine, ancestor of hydroxychloroquine. Immune reaction may result from activation of endothelial cells through drug-dependent antibodies with sudden systemic symptoms such as anuria 2 . There are also rare case reports in the literature on the development of thrombocytopenia with hydroxychloroquine therapy. Fromm et al reported a case of thrombotic thrombocytopenic purpura, which is in the spectrum of thrombotic microangiopathy, in a 64-year-old patient with rheumatoid arthritis following exposure to three doses of hydroxychloroquine 3 . The authors noted that the reaction was similar to quinine-associated thrombotic microangiopathy and proposed a shared mechanism for the adverse effect. In another case report, Mar et al. described a patient with systemic lupus erythematosus who developed thrombotic thrombocytopenic purpura shortly after commencing on hydroxychloroquine. 4 In conclusion, from its origins as an anti-malarial drug in the late 1600s to its current use in various rheumatic diseases, there is still a lot of unknowns about hydroxychloroquine not only with respect to its mechanism of action but also its side-effect profile. Judicious use and careful monitoring of drug-related side-effect are crucial with off-label use of any agent during this pandemic.

J o u r n a l P r e -p r o o f

Thrombotic microangiopathy in a patient with COVID-19

Syndromes of thrombotic microangiopathy

Suspected hydroxychloroquine-induced thrombotic thrombocytopaenic purpura

Acquired thrombotic thrombocytopenic purpura: Puzzles, curiosities and conundrums

The author wants to thank Dr. Doris Chan for proofreading.

The author declared no competing interests.